Haga una pregunta para buscar información del producto y recursos médicos de Lilly. Para activar la búsqueda escriba 3 términos.
Por favor no use este campo para reportar eventos adverso o quejas de productos.
Para reportar un evento adverso de los productos de Lilly, por favor póngase en contacto con nosotros por correo electrónico a email@example.com y en caso de una queja de producto al siguiente correo electrónico firstname.lastname@example.org.
La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.
What is the mechanism of action of galcanezumab in migraine prevention?
Galcanezumab is a humanized IgG4 mAb that binds CGRP and prevents its biological activity without blocking the CGRP receptor.
The information contained in this letter may not completely match the current local labeling for GALCANEZUMAB. Please see local labeling approved in your country.
Mechanism of Action of Galcanezumab
Galcanezumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) that
Galcanezumab targets CGRP and binds with high
When galcanezumab is administered, the premise is that
- CGRP will bind to galcanezumab, and
- the amount of free CGRP that is available to interact with the CGRP receptors will be reduced.1
Galcanezumab-bound CGRP is expected to take on the disposition characteristics of galcanezumab resulting in
- a lower clearance than free CGRP, and
- an increase in total CGRP concentration upon galcanezumab administration.1
In the phase 3, double-blind, placebo-controlled migraine prevention studies,5-7 total CGRP concentrations increased after galcanezumab administration compared to placebo. This indicated that the antibody was
The binding of galcanezumab to CGRP is slowly reversible based on the off-rate for the CGRP/galcanezumab interaction determined experimentally. However, any released CGRP is likely to be quickly bound to the same or a different antibody based on the rapid on-rate for binding.4
Being a macromolecule, galcanezumab does not appreciably cross the blood-brain barrier. Therefore, it is thought that galcanezumab acts peripherally in structures involved in migraine pathogenesis, including the trigeminal ganglia.8-10
The Role of Calcitonin Gene-Related Peptide in Migraine
- a 37-amino acid peptide commonly found in the peripheral and central nervous systems, and
- considered a potent vasodilator in both the peripheral and cerebral vasculature.11,12
It has a potency approximately
- 10 times higher than the most potent prostaglandins, and
- 10 to 100 times greater than acetylcholine and neuropeptide substance P.11
The CGRP neuropeptide has a wide range of physiological actions including cardiovascular regulatory processes and other conditions including but not limited to neurogenic inflammation, pain, and migraine. Migraine pathogenesis is thought to be associated with the activation of the trigeminovascular system. CGRP is distributed throughout the trigeminovascular system and is released from trigeminal ganglia nerves upon activation.11
The role of CGRP in migraine has been underscored by several experimental and clinical findings including
- an increase of jugular CGRP venous blood concentration during spontaneous migraine attacks
- intravenous (IV) infusion of recombinant human CGRP triggered a migraine attack in migraine sufferers
- elevated CGRP serum concentrations were inhibited by triptan treatment, and
- small-molecule CGRP receptor antagonists were effective in relieving acute migraine headache in double-blind, randomized, placebo-controlled trials.3,12,13